Relief Therapeutics Holding SA Business Summary

Relief Therapeutics Holding SA (RLFTY), which transitioned into MindMaze Therapeutics Holding SA following a December 2025 business combination with NeuroX Group, operates as a hybrid biopharmaceutical and digital neurotherapeutics company. The firm generates revenue through a dual-stream model: licensing and distribution royalties from its rare disease biopharma portfolio and transaction-based fees from its AI-driven digital health platform. Primary business segments include Rare Metabolic Disorders (featuring OLPRUVA for urea cycle disorders and PKU GOLIKE), Rare Dermatological Diseases (lead candidate RLF-TD011 for epidermolysis bullosa), and Digital Neurotherapeutics, which utilizes software-delivered clinical interventions for neurological recovery. Positioned as a pioneer in drug-digital integration, the company competes directly with rare disease specialists such as Santhera Pharmaceuticals, Idorsia Pharmaceuticals, and Genfit, distinguishing itself by combining traditional peptide biology with a proprietary brain-technology platform. The leadership team is led by CEO Alexandre Capet, a life sciences veteran with over 25 years of experience at Bayer, Sanofi, and Voluntis, and CTO Frédéric Condolo, who previously held senior technical roles at Ubisoft and Valiantys. Jeremy Meinen, a Swiss certified public accountant with over a decade of financial management experience, continues as Chief Financial Officer, while Paolo Galfetti serves as Chief Business Officer. The Board of Directors is chaired by Walid Hanna, founder of MedVent Group and CEO of Perseus Biomics, and includes notable members such as cognitive neuroprosthetics expert Olaf Blanke and former Franklin Templeton executive Gregory Van Beek. The company is backed by institutional investors including Global Emerging Markets (GEM), with the post-merger ownership structure heavily concentrated among former NeuroX shareholders who hold approximately 91.75% of the combined entity.